Critical Care
Randomized trial: Procalcitonin to reduce long-term infection-associated adverse events in sepsis
15 Feb, 2021 | 00:43h | UTC
Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19
15 Feb, 2021 | 01:18h | UTCCommentaries: Preventive blood thinning drugs could reduce COVID hospital deaths – London School of Hygiene & Tropical Medicine AND Preventive blood thinning drugs linked to reduced risk of death in COVID-19 patients – The BMJ AND Expert reaction to a study looking at prophylactic anticoagulants as a treatment for hospitalised patients with COVID-19 – Science Media Centre AND
Commentary on Twitter
Blood thinning drugs are now linked to a reduced risk of death for COVID19 patients. Those given preventive blood thinners (prophylactic anticoagulants) within 24 hours of hospital admission for Covid were less likely to die. New report in the BMJ https://t.co/KQqQ3Zoj8B pic.twitter.com/6wJj8mEucw
— delthia ricks ? (@DelthiaRicks) February 12, 2021
Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US
15 Feb, 2021 | 01:13h | UTCAuthor interview: COVID-19 Vaccine Safety–Anaphylaxis and Allergic Reactions – JAMA
Commentary on Twitter
More than 17.5 million doses of Pfizer & Moderna vaccine were administered between Dec 14 – Jan 18, in USA.
Only 66 cases of anaphylaxis were reported & all but 1 case occurred within 11 min of vaccination.
0 deaths.https://t.co/P1YJISkHZE
— Isaac Bogoch (@BogochIsaac) February 12, 2021
RCT: Tocilizumab reduces deaths in patients hospitalized with COVID-19
12 Feb, 2021 | 02:25h | UTCNews release: Tocilizumab reduces deaths in patients hospitalised with COVID-19 – University of Oxford
Commentary: Tocilizumab cuts death rate in severe COVID-19, study finds – CIDRAP
Commentary on Twitter
?RECOVERY pre-print:
Tocilizumab
– reduces mortality
– shortens hospital stay
– reduces progression to invasive mechanical ventilationClear benefits on top of corticosteroids
Good news!https://t.co/dal17tQG5b
— Martin Landray (@MartinLandray) February 11, 2021
Guidelines for extracorporeal cardiopulmonary resuscitation in children and adults
11 Feb, 2021 | 01:48h | UTCSee also: Pediatric Extracorporeal Cardiopulmonary Resuscitation ELSO Guidelines – ASAIO Journal
Commentary on Twitter
#ECPR in adults @ELSOOrg guidelines
?pt selection, timing & location
?rationale for VA #ECPR
?cannula/cannulation
?#ACLS modifications
?establishing #ECMO & specific post CA care
?coronary angiography/PCI & imaging
?weaning@asaiojournal #FOAMecmo https://t.co/uDrPuSTTpg pic.twitter.com/A1ri9mn56s— M Velia Antonini (@FOAMecmo) February 1, 2021
Combination of vancomycin plus piperacillin and risk of acute kidney injury: a worldwide pharmacovigilance database analysis
11 Feb, 2021 | 01:50h | UTCRelated: Risk of acute kidney injury and Clostridioides difficile infection with piperacillin/tazobactam, cefepime and meropenem with or without vancomycin – Clinical Infectious Diseases AND Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis – Critical Care Medicine (link to abstract – $ for full-text) AND Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children – JAMA Pediatrics (link to abstract – $ for full-text) AND Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients – Critical Care
Commentary on Twitter
? New paper from our team @HopitalCochin ⤵️
New data supporting a drug-drug interaction between vancomycin and piperacillin ⚠️ increased risk of acute kidney injury | Great collab with @AdrienContejean@KerneisSolen
Read more in @BSACandJAC ⤵️https://t.co/eQW5s52fOY@ABsteward— Laurent Chouchana (@LChouchana) February 1, 2021
Case report: Severe reinfection with South African SARS-CoV-2 variant
11 Feb, 2021 | 02:17h | UTC
Commentary on Twitter
?NEW Case report ?#CID @IDSAInfo
Severe reinfection with South African SARS-CoV-2 501Y.V2 lineage B.1.351 variant four months after a first mild infection. @InfectiousDz https://t.co/zjjJED4r0D— Antibiotic Steward? Bassam Ghanem (@ABsteward) February 10, 2021
ACP: Update on Remdesivir use for hospitalized COVID-19 patients
11 Feb, 2021 | 02:15h | UTC
Cohort study: Adjunctive clindamycin may benefit beta-lactam antibiotic-treated patients with invasive beta-hemolytic streptococcal infections
10 Feb, 2021 | 01:13h | UTCEffectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter
Our new study in Lancet ID ?? showing a potential role for wider adjunctive use of clindamycin for iGAS even without next fasc or toxic shock. Utility in non-A,non-B strep questionable. Congratulations to stellar first author @Ahmed_HBabiker https://t.co/3t4FsmClWa
— Sameer Kadri (@SameerKadri12) December 15, 2020
Choosing Wisely for Critical Care: The Next Five
9 Feb, 2021 | 01:07h | UTCChoosing Wisely For Critical Care: The Next Five – Critical Care Medicine
See complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
Commentary on Twitter
Critical Care Choosing Wisely: The Next Five
?Don't retain catheters/drains w/o an indication
?Don't delay liberation from MV
?Don't continue antibiotics unnecessarily
?Don't delay mobilizing patients
?Don't provide goal-discordant carehttps://t.co/kSsMh33Okc pic.twitter.com/V9zGb2MLXY— Başak Çoruh (@basakcoruhUW) February 1, 2021
Review: Nosocomial infection in the ICU setting
9 Feb, 2021 | 01:05h | UTCNosocomial Infection – Critical Care Medicine
Thrombosis and COVID-19: Controversies and (Tentative) Conclusions
9 Feb, 2021 | 01:41h | UTCThrombosis and COVID-19: Controversies and (Tentative) Conclusions – Clinical Infectious Diseases
Commentary on Twitter
Excellent review of thrombosis and anticoagulation in #COVID19 by @connors_md and @RMKGandhi
Paradoxically, anticoagulation may be most beneficial in moderately ill patients with #COVID19, as the bleeding risk may be excessive in the critically ill https://t.co/75TiNs0iej pic.twitter.com/v0avzhFl3f
— John Ross (@JohnRossMD) February 6, 2021
Mitigating inequities and saving lives with ICU triage during the COVID-19 pandemic
9 Feb, 2021 | 01:29h | UTC
ARDS: Contemporary management and novel approaches during COVID-19
9 Feb, 2021 | 01:31h | UTC
Commentary on Twitter
Review Article: Acute Respiratory Distress Syndrome #ARDS: Contemporary Management and Novel Approaches during #COVID19 https://t.co/Hbsuejegos pic.twitter.com/9rOyZmOWpA
— Anesthesiology journal (@_Anesthesiology) February 5, 2021
RCT: Posaconazole noninferior to voriconazole for primary treatment of invasive aspergillosis
7 Feb, 2021 | 21:00h | UTCPosaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Guideline synopsis: Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy
7 Feb, 2021 | 20:55h | UTCManagement of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy – JAMA (free for a limited period)
Audio Clinical Review: Management of Immunotherapy-Related Toxicities
Original guideline and other resources: NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities
Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma
7 Feb, 2021 | 21:32h | UTCSARS-CoV-2 evolution during treatment of chronic infection – Nature
Commentary on Twitter
Just published @nature: The evolution of #SARSCoV2 in an immunocompromised patient, over > 100 days, that markedly accelerated once treated w/ convalescent plasma, with mutations that altered the response to neutralizing antibodies, by @GuptaR_lab https://t.co/SI4QL6BRXe pic.twitter.com/wqI1C2EYjQ
— Eric Topol (@EricTopol) February 5, 2021
SR/MA: ICU mortality from COVID-19 continued to fall in 2020, but improvement is slowing
7 Feb, 2021 | 21:18h | UTCNews release: ICU mortality from COVID-19 continued to fall in 2020, but improvement is slowing – University of Bristol
Original article: Mortality in patients admitted to intensive care with COVID‐19: an updated systematic review and meta‐analysis of observational studies – Anaesthesia
Commentary on Twitter
?Has mortality from COVID‐19 in patients admitted to the ICU changed again?@drrichstrong, @adk300, @emirakur and @doctimcook update their previous analysis and find that any fall in mortality rate between June and September appears to have plateaued.
?https://t.co/zp8ygzp78A pic.twitter.com/g21p3rcjY6
— ??????????? (@Anaes_Journal) February 2, 2021
Cohort study: ECMO in patients with severe respiratory failure from COVID-19
7 Feb, 2021 | 21:16h | UTCRelated: ECMO for COVID-19 patients in Europe and Israel – Intensive Care Medicine
Commentaries on Twitter
#ECMO in #COVID19, multicenter US based study on 5122 critical adults
➡️#ECLS in 3.7%, 66.8% of whom survived to hospital discharge or 60 days
➡️considerably reduced mortality with early ECMO in severe hypoxemic respiratory failure vs conventional approachhttps://t.co/OgS7Q5tctS pic.twitter.com/PO5O8t3l8F— Intens Care Med (@yourICM) February 4, 2021
Online today @yourICM, our important multicenter descriptive and trial emulation work around #ECMO and #COVID19 @BIDMCAnesthesia @DavidLeaf9 @SamanthaSkb273 @_MiguelHernan from the STOP-COVID Investigators https://t.co/DuhWufYqZ3 pic.twitter.com/nXPvKDYMYL
— Shaz Shaefi (@SShaefi) February 2, 2021
What’s the risk of dying from a fast-spreading COVID-19 variant?
7 Feb, 2021 | 21:21h | UTCWhat’s the risk of dying from a fast-spreading COVID-19 variant? – Nature
Original study: Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01 – medRxiv
Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19
7 Feb, 2021 | 21:13h | UTC“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia
SR/MA: Colistin nephrotoxicity
5 Feb, 2021 | 01:21h | UTC
NIH Treatment Guideline Update: “there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of COVID-19”
5 Feb, 2021 | 01:44h | UTC
Dialysis patients have 4-fold greater risk of dying from COVID-19
5 Feb, 2021 | 01:39h | UTCNews Release: Dialysis patients have 4-fold greater risk of dying from COVID-19 – Canadian Medical Association Journal
Original Study: COVID-19 in patients undergoing long-term dialysis in Ontario – Canadian Medical Association Journal
Randomized trial: Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension
4 Feb, 2021 | 01:18h | UTC
Commentary on Twitter
Does induced hypothermia/targetted temp management improve outcomes in patients with traumatic brain injury?
Maybe or maybe not
But this trial slow to cool, not very cool, underpowered and mod rate of dropout
Prob does not answer questionhttps://t.co/UGRFmUVNV0 pic.twitter.com/c0iDqj2l2e
— Graham Nichol (@grahamnichol) January 29, 2021